


Supplementary Figure 1. Triple endpoint survival in patients with non-Hodgkin's lymphoma stratified by treatment group



The graph shows triple endpoint survival in patients with non-Hodgkin's lymphoma (NHL) who were enrolled in the long-term follow-up study of patients with NHL who had received plerixafor or placebo in combination with granulocyte colony-stimulating factor for stem cell mobilization. A *triple endpoint event* was defined as death, progression, relapse, or introduction of additional medication for NHL, whichever came first. Assessment of triple endpoint survival over 5 years showed no statistically significant difference (log-rank, $P = .702$; Wilcoxon, $P = .836$) between the 2 treatment groups.